What FDA‑approved pharmacologic agents are available for chronic obesity management, including their dosing regimens and associated side effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FDA-Approved Obesity Medications: Dosing and Side Effects

Semaglutide 2.4 mg should be prioritized as first-line pharmacotherapy for most patients with obesity, given its superior weight loss efficacy (average 15% total body weight loss) and favorable benefit-risk profile 1.

First-Tier Agents

Semaglutide 2.4 mg (Wegovy)

  • Dosing: Start 0.25 mg subcutaneously weekly, titrate monthly: 0.5 mg → 1.0 mg → 1.7 mg → maintenance 2.4 mg weekly 1
  • Side Effects:
    • Nausea and vomiting (dose-dependent, mitigated by gradual titration)
    • Increased risk of pancreatitis and gallbladder disease
    • Delayed gastric emptying 1
  • Key Advantage: Glucoregulatory benefits; also approved for type 2 diabetes 1

Tirzepatide

  • Dosing: Emerging as highly effective with even greater weight loss than semaglutide in phase 3 trials 2, 3, 4
  • Side Effects: Similar GI profile to GLP-1 agonists 3
  • Note: Represents next-generation dual/triple receptor agonist technology 3

Second-Tier Agents

Liraglutide 3.0 mg (Saxenda)

  • Dosing: Start 0.6 mg subcutaneously daily, increase weekly by 0.6 mg to maintenance 3.0 mg daily 1
  • Side Effects:
    • Nausea and vomiting (requires gradual titration)
    • Pancreatitis and gallbladder disease risk
    • Delayed gastric emptying 1
  • Clinical Context: Glucoregulatory benefits; dual indication for type 2 diabetes 1

Phentermine-Topiramate ER (Qsymia)

  • Dosing: Start 3.75/23 mg daily for 14 days, then 7.5/46 mg daily; may increase to 11.25/69 mg or maximum 15/92 mg daily 1
  • Side Effects:
    • Cardiovascular: Increased heart rate and blood pressure
    • Teratogenicity (topiramate) - requires effective contraception in women of childbearing potential
    • Cognitive effects (topiramate component) 1
  • Monitoring: Blood pressure and heart rate periodically 1
  • Contraindications: History of cardiovascular disease, uncontrolled hypertension 1
  • Preferred Use: Patients with comorbid migraines 1

Naltrexone-Bupropion ER (Contrave)

  • Dosing: Titrate over 4 weeks: Week 1: 8/90 mg daily → Week 2: 8/90 mg twice daily → Week 3: 16/180 mg AM, 8/90 mg PM → Week 4+: 16/180 mg twice daily (maintenance) 1
  • Side Effects:
    • Seizure risk (bupropion component)
    • Increased blood pressure and heart rate
    • Psychiatric effects 1
  • Monitoring: Blood pressure and heart rate, especially first 12 weeks 1
  • Contraindications: Seizure disorders, concurrent opiate use 1
  • Preferred Use: Patients attempting smoking cessation or with comorbid depression 1

Not Recommended

Orlistat (Xenical, Alli)

  • AGA Position: Suggests against routine use 1
  • Dosing: 120 mg three times daily with meals
  • Side Effects:
    • Significant GI adverse effects (fecal urgency, oily spotting, flatulence)
    • Fat-soluble vitamin malabsorption 1
  • Required: Daily multivitamin supplementation 1
  • Rationale for Non-Recommendation: Minimal weight loss benefit (2.6 kg vs placebo) with substantial GI burden 5
  • Exception: May be reasonable for patients who highly value even small weight loss and can tolerate GI effects 1

Phentermine (Monotherapy)

  • Status: FDA-approved but only for short-term use (≤12 weeks) 2, 6
  • Note: Not recommended for chronic obesity management; included in combination product above 6

Specialized Agent

Setmelanotide

  • Indication: Ultra-rare genetic obesity syndromes (e.g., POMC, PCSK1, LEPR deficiency) 4, 6
  • Note: Outside scope of general obesity management 1

Critical Implementation Points

All anti-obesity medications must be used chronically, not short-term 1. Weight regain occurs with discontinuation.

Medication selection algorithm:

  1. Default choice: Semaglutide 2.4 mg (highest efficacy, moderate evidence) 1
  2. If comorbid migraines: Phentermine-topiramate ER 1
  3. If attempting smoking cessation or depression: Naltrexone-bupropion ER 1
  4. If cardiovascular disease or uncontrolled hypertension: Avoid phentermine-topiramate; use GLP-1 agonists 1
  5. If seizure history: Avoid naltrexone-bupropion 1
  6. If on chronic opiates: Avoid naltrexone-bupropion 1
  7. If women of childbearing potential: Avoid phentermine-topiramate unless using reliable contraception 1

Comparative Efficacy Data

At 52 weeks, proportion achieving ≥5% weight loss 5:

  • Phentermine-topiramate: 75% (OR 9.22 vs placebo)
  • Liraglutide: 63% (OR 5.54 vs placebo)
  • Naltrexone-bupropion: 55% (OR 3.96 vs placebo)
  • Lorcaserin: 49% (OR 3.10 vs placebo) - Note: withdrawn from market
  • Orlistat: 44% (OR 2.70 vs placebo)
  • Placebo: 23%

Mean excess weight loss vs placebo 5:

  • Phentermine-topiramate: -8.8 kg
  • Liraglutide: -5.3 kg
  • Naltrexone-bupropion: -5.0 kg
  • Orlistat: -2.6 kg

Common Pitfalls

  1. Discontinuing medications after initial weight loss: Obesity is chronic; medications require indefinite continuation 1
  2. Inadequate dose titration: GLP-1 agonist GI side effects are minimized by gradual titration 1
  3. Failing to screen for contraindications: Particularly teratogenicity (phentermine-topiramate), seizure risk (naltrexone-bupropion), and cardiovascular disease (phentermine-topiramate) 1
  4. Not monitoring vital signs: Blood pressure and heart rate monitoring required for phentermine-containing and naltrexone-bupropion products 1
  5. Using orlistat as first-line: Minimal efficacy with high GI burden 1, 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.